Insider

Merck released third-quarter 2026 results

Merck & Co., Inc. reported third-quarter 2026 results with earnings per share (EPS) of $2.04 under generally accepted accounting principles (GAAP) and $2.49 on a non-GAAP basis. The quarter included a $400 million one-time charge for a new license agreement and lower revenue from the Koselugo alliance, which followed a 2025 contract restructuring.

Verified against 2 archived primary sources · SHA-256 recorded Inspect sources & citations ↓
a long hallway with pictures on the walls
Photo by zhang shuaizhang on Unsplash
$2.04
GAAP EPS
$2.49
Non-GAAP EPS
7%
R&D expense increase

Key points

  • GAAP EPS was $2.04 in the third quarter of 2026, while non-GAAP EPS was $2.49.
  • Merck recorded a net loss for the first nine months of 2026, resulting in the exclusion of potential dilutive common shares from the EPS calculation.

Key financial highlights and expenses.

GAAP EPS was $2.04 in the third quarter of 2026, while non-GAAP EPS was $2.49. Profitability was impacted by a $400 million one-time charge related to a global license agreement with SciBrunch to develop a KRAS G12D inhibitor.

Operating expenses rose year-over-year. Research and development (R&D) expenses increased 7% to $4.5 billion, and selling, general and administrative (SG&A) expenses rose 10% to $2.9 billion.

Koselugo alliance revenue was $13 million in the third quarter of 2026, down from $214 million in the third quarter of 2025. The decline stems from a 2025 contract amendment with AstraZeneca that discontinued revenue sharing.

Third-quarter 2026 EPS.

GAAP EPS.$2.04Non-GAAP EPS.$2.49
Data from the original sources listed alongside.

Revenue by quarter, $B

15.6Q4 '24*15.5Q1 '2515.8Q2 '2517.3Q3 '2516.4Q4 '25*16.3Q1 '2616.6Q2 '2618.1Q3 '26
Q4 = fiscal year minus the three quarters reported on their own. Revenue as the company tagged it in its SEC filings (XBRL). Guidance is the company's own, not our forecast.

Sector context: 36 covered companies in Health Care reported a median revenue change of +7.2% YoY in their latest filings.

Regulatory events and risks.

Merck recorded a net loss for the first nine months of 2026, resulting in the exclusion of potential dilutive common shares from the EPS calculation.

Despite financial fluctuations, the company advanced its drug portfolio. It received approvals for WELIREG in the U.S., KEYTRUDA in the EU, and KEYJECT in Japan. The FDA also accepted a supplemental biologics license application (sBLA) for ENFLONSIA.

Outlook.

Investors are watching March 22, 2027, the PDUFA date for ENFLONSIA. Future reports will show if Merck meets its 2026 financial targets.

Original sources

  1. 8-K filing, October 29, 2026October 29, 2026SHA-256 of our archived copy 0a14ceb3d9fe…
  2. 8-K EX-99.1 filing, October 29, 2026October 29, 2026SHA-256 of our archived copy 13bed953645b…
Cite this article

The fingerprint identifies the exact version of each original that the article was written from; the original stays at its source.

Prepared by AI from official company documents; automatic checks and an AI editor review it before publication, and not every article is read by a person. This is not investment advice. Editorial standards